Printer Friendly Printed from http://www.researchandmarkets.com/reports/336108 An Evaluation of Products and Technologies for Molecular Diagnostics within Oncology Description: This latest Multi Client Publication provides: - An overview of current industry-landscape for molecular diagnostics within the oncology area - Analysis of the key European markets including forecasts for growth, drivers and restraints in the marketplace - Reimbursement and legislation environment, the most relevant national guidelines relating to genetic testing - Understanding of market opportunities for molecular diagnostics within the oncology market as an area of growth, research and future developments - Data in Excel Spreadsheet The primary objective of this report, compiled from an analysis of primary and secondary research data, is to provide an overview of the molecular diagnostics market for selected oncology markers in the country markets listed below. - France - Germany - Italy - United Kingdom - USA The following key issues have been addressed: - Provide a reflective picture of the type and number of relevant testing institutions - Which and how many parameters are tested (market size). Top 3 solid markers, top 3 lymphoid markers and emerging markers identified. - Which assays are used (home brew or commercial) - Current market growth per parameter - Expected market growth rates per parameter in the next 5 years - Which technologies are used (PCR, RT-PCR, FISH, sequencing, microarrays, others) and what is the anticipated shift in use of these. - Devices used - The regulatory issues per country (legislation, reimbursement etc.) - Future trends & emerging technologies Contents: Introduction Part 1 – France 1 Current Situation 1.1 Respondent Population France 1.2 Nucleic Acid Based Testing 1.3 Genetic Testing - Routine or Research 1.4 HPV Testing 1.5 Oncology Markers 1.5.1 Solid Tumor Marker 1.5.2 Lymphoid Tumour Marker 1.6 Nucleic Acid Sample Preparation 1.7 Trends in NA-Based Oncology Diagnostics 1.7.1 Emerging Markers 1.7.2 CE approval 1.8 NAT - application and technical appraisal 1.9 Politics and Reimbursement 1.9.1 Drivers of NAT 1.9.2 Restraints on NAT 1.10 Summary and Conclusions Part 2 – Germany 2 Current Situation 2.1 Respondent Population Germany 2.2 Nucleic Acid Based Testing 2.3 Genetic Testing - Routine or Research 2.4 HPV Testing 2.5 Oncology Markers 2.5.1 Solid Tumor Marker 2.5.2 Lymphoid Tumor Marker 2.6 Nucleic Acid Sample Preparation 2.7 Trends in Genetics Based Oncology Diagnostics 2.7.1 Emerging Markers 2.7.2 CE certification 2.8 NAT - application and technical appraisal 2.9 Politics and Reimbursement 2.9.1 Drivers of NAT 2.9.2 Restraints on NAT 2.10 Summary and Conclusions Part 3 – Italy 3 Current Situation 3.1 Respondent Population – Italy 3.2 Nucleic Acid Based Testing 3.2.1 Types of testing performed 3.3 Genetic Testing - Routine or Research 3.4 HPV Testing 3.5 Oncology Markers 3.5.1 Solid Tumor Marker 3.5.2 Lymphoid Tumor Marker 3.6 Nucleic Acid Sample Preparation 3.7 Trends in NA-Based Oncology Diagnostics 3.7.1 Emerging Markers 3.7.2 CE or FDA approval 3.8 NAT - application and technical appraisal 3.9 Politics and Reimbursement 3.9.1 Drivers of NAT 3.9.2 Restraints on NAT 3.10 Summary and Conclusions Part 4 – United Kingdom 4 Current Situation 4.1 Respondent Population UK 4.2 Nucleic Acid Based Testing 4.3 Genetic Testing - Routine or Research 4.4 HPV Testing 4.5 Oncology Markers 4.5.1 Solid Tumor Marker 4.5.2 Lymphoid Tumor Marker 4.6 Nucleic Acid Sample Preparation 4.7 Trends in NA-Based Oncology Diagnostics 4.7.2 Emerging Markers 4.7.3 CE certification 4.8 NAT - application and technical appraisal 4.9 Politics and Reimbursement 4.9.1 Drivers of NAT 4.9.2 Restraints on NAT 4.10 Summary and Conclusions Part 5 – USA 5 Current Situation 5.1 Respondent Population US 5.2 Nucleic Acid Based Testing 5.2.1 Types of testing performed 5.3 Genetic Testing - Routine or Research 5.4 HPV Testing 5.5 Oncology Markers 5.5.1 Solid Tumor Marker 5.5.2 Lymphoid Tumor Marker 5.6 Nucleic Acid Sample Preparation 5.7 Trends in NA-Based Oncology Diagnostics 5.7.1 Emerging Marker 5.7.2 Test Certification 5.8 NAT - application and technical appraisal 5.9 Politics and Reimbursement 5.9.1 Drivers of NAT 5.9.2 Restraints on NAT 5.10 Summary and Conclusions Methodology Interview numbers were selected to ensure an accurate representation of the country laboratory structures, which vary widely and are described within the report. The study focuses on institutions that have a specialization in Oncology and Molecular Diagnostics. There is no differentiation between public and private laboratories; however, where differences, relevant for the analysis were found to be obvious, these are highlighted. Target respondents were Heads of Departments or senior personnel able to provide sufficient qualitative answers based upon their experience within the clinical diagnostic laboratory setting. The information gathering was carried out blind. To support the primary data the author utilised a combination of internal and external secondary data to provide further input to the overall analysis. To allow an interpretation for the whole market segment, the findings from primary research were projected onto the base population (laboratories performing nucleic acid based testing in oncology) which was determined by the first level of primary research in the form of snapshot interviews. Interviews were conducted with respondents within at least 16 laboratories per country. Ordering: Order Online - visit http://www.researchandmarkets.com/reports/336108 Order by Fax - using the order form below Order By Post - print the order form below and send to Research and Markets, Guinness Centre, Taylors Lane, Dublin 8, Ireland. Page 1 of 2 Printed 30/08/2008 16:02:08 Fax Order Form To place an order via fax simply print this form, fill in the information below and fax the completed form to the number at the bottom of this page. If you have any questions please email help@researchandmarkets.com Order information Please verify that the product information is correct and select the format you require. Product Name: An Evaluation of Products and Technologies for Molecular Diagnostics within Oncology Web Address: http://www.researchandmarkets.com/reports/336108 Office Code: OCHGMLMQQVQ Report formats Please enter the quantity of the report format you require. Format Quantity Price Electronic (PDF) €4,400.00 Hard Copy €4,439.00 + EUR€ 50.00 Shipping/Handling * * Shipping/Handling is only charged once per order. Contact information Please enter all the information below in BLOCK CAPITALS. First Name:   Last Name:   Email Address: Job Title: Organisation: Address: City: Postal/Zip Code: Country: Phone Number: Fax Number: Please fax this form to: (646)607-1907 or (646)964-6609 - From USA +353-1-481-1716 or +353-1-653-1571 - From Rest of World Page 2 of 2 Printed 30/08/2008 16:02:08 Payment information Please indicate the payment method you would like to use by selecting the appropriate box.  Pay by Credit Card: American Express Diners Club Master Card Visa Cardholder Name: Expiry Date: / Card Number: CVV Security Code: Issue Date: /   (Diners Club only)  Pay by Check: Please post the check, accompanied by this form, to: Research and Markets, Guinness Centre, Taylors Lane, Dublin 8, Ireland.  Pay by Wire Transfer: Please transfer funds to: Account number: 83313083 Sort code: 98-53-30 Swift code: ULSBIE2D IBAN number: IE78ULSB98533083313083 Bank Address: Ulster Bank, 27-35 Main St, Blackrock, Co. Dublin, Ireland. If you have a Marketing Code please enter it below: Marketing Code: Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp Please fax this form to: (646)607-1907 or (646)964-6609 - From USA +353-1-481-1716 or +353-1-653-1571 - From Rest of World